Can new computer software technology be used to help place the pacing lead on the left side of the heart in the most beneficial position when a participant has a cardiac resynchronisation therapy device (CRT-D) implant?
| ISRCTN | ISRCTN91522248 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN91522248 |
| Secondary identifying numbers | 41689 |
- Submission date
- 24/06/2019
- Registration date
- 02/07/2019
- Last edited
- 23/05/2020
- Recruitment status
- Suspended
- Overall study status
- Completed
- Condition category
- Circulatory System
Plain English summary of protocol
Background and study aims
Researchers have known for some time that certain people who have heart failure may benefit from having a special pacemaker implanted which aims to make the pumping chambers of the heart beat more efficiently. To make the heart pump as efficiently as possible it is necessary to place the pacing leads in good positions. The CRT device lead to the left side of the heart is very important as this is responsible for re-coordinating the heart’s contraction. This, however, is the most technically challenging part of the CRT implant and there are often a variety of different options in terms of where the lead to the left side of heart is placed. This study aims to see whether new advanced imaging technologies and computer software can be used to help guide lead placement and thus allow more people to respond to treatment.
Who can participate?
Patients aged 18 or over who require a Cardiac Resynchronisation Therapy Device (CRT-D)
What does the study involve?
Participants are randomly allocated to either standard treatment or to an advanced technology group. The patients in the advanced technology group undergo special imaging (cardiac MR and 2D echo) before implantation of their pacemaker. The images obtained are superimposed on to the standard X-ray images usually taken during the procedure using special computer software that has been newly developed. The idea is that the patient’s anatomical data (coronary veins, scar) and physiological dyssynchrony (assessment of the coordination of heart muscle contraction) information derived from these imaging techniques will help the operator implant the lead and also choose the best site for it.
What are the possible benefits and risks of participating?
There may be no benefit from participating in this study as it is not known whether having an extra heart scan (MRI) and using this information to guide the CRT implant will help improve the response to CRT device therapy. Some participants may be unable to undergo an MRI scan if they are claustrophobic.
Where is the study run from?
Guys and St Thomas NHS Foundation Trust (UK)
When is the study starting and how long is it expected to run for?
November 2018 to July 2022
Who is funding the study?
Siemens Healthcare GmbH
Who is the main contact?
Matthew Osmond
Matthew.osmond@gstt.nhs.uk
Contact information
Public
1st Floor Gassiot House
St Thomas’ Hospital
Westminster Bridge Road
London
SE1 7EH
United Kingdom
| Matthew.osmond@gstt.nhs.uk |
Study information
| Study design | Randomised; Interventional; Design type: Treatment, Device |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
| Scientific title | A prospective randomised multi-centre Trial comparing cArdiac MRI guided CRT versus Conventional CRT implantation in patients with Ischaemic Cardiomyopathy - TACTIC CRT |
| Study acronym | TACTIC CRT |
| Study objectives | The principal question is to find out whether there is a difference in the proportion of patients responding to treatment in the conventional treatment arm of the study compared to the advanced imaging arm. The secondary research objectives are to see whether patients' left ventricles have reduced in size (often referred to as remodelling). The left ventricle (the main pumping chamber of the heart) usually becomes quite large in heart failure and therefore the researchers hope to see a reduction in the size of the left ventricle following cardiac resynchronisation therapy (CRT) pacing. CRT pacemakers are specialised heart failure pacemakers. The researchers will be able to judge whether the left ventricle has reduced in size by an ultrasound scan before and after the CRT pacemaker procedure. They will also assess how far patients can walk over 6 minutes and perform a symptom questionnaire before and after the procedure to assess their response to the treatment. |
| Ethics approval(s) | Approved 10/06/2019, London – Stanmore Research Ethics Committee (Health Research Authority, Skipton House, 80 London Road, London, SE1 6LH; Tel: +44 (0)20 7972 2561; Email: NRESCommittee.London-Stanmore@nhs.net), ref: 19/LO/0461 |
| Health condition(s) or problem(s) studied | Ischaemic cardiomyopathy |
| Intervention | Patients in this study receiving CRT will be randomly assigned to either an ‘advanced technology’ arm or a conventional treatment arm. In the advanced technology arm, cardiac MR scans will be used to get 2D images of the heart anatomy and scar. Special computer software will then be used to superimpose these pictures on x-ray images at the time of implantation. MR and 2D echo data will then be used to determine the best site for lead placement by identifying the area of maximal mechanical delay (last area of the heart to contract). Pacing in this area should improve the overall function of the heart the most. Pre-implant assessment All patients will answer an MLHF questionnaire and undergo a 12 lead ECG. All patients will have an ultrasound of their heart (echo). This will measure the size of the left ventricle (main heart pumping chamber) so that the response to CRT can be measured after the implant (the size is expected to decrease if the patient responds to treatment). Patients in the control arm will otherwise undergo the standard CRT implantation treatment. The Advanced Imaging Arm Pre-procedure, patients will undergo a cardiac MR scan to assess anatomy, scar, function, volumes and mechanical delay of the left ventricle. At implant, the MR images will be superimposed on to the x-ray images usually used at implant, using computer technology that has been developed by KCL Imaging Sciences Department and Philips Medical Systems. This will allow the anatomy of the heart veins and scar tissue to be available for planning and performance of the pacemaker implant. Using special computer software, the researchers will also superimpose the site of latest mechanical activation of the left heart from the MR and echo data on to the x-ray screen. This information will help to choose the ideal site for pacemaker lead placement i.e. away from scar but in an area of late contraction. Post implant Patients will be seen 4-8 weeks after their implant for a pacing check. At 6 months post-implant, patients will answer a MLHF questionnaire and undergo a 12 lead ECG and an echo to assess their response to therapy. |
| Intervention type | Device |
| Pharmaceutical study type(s) | |
| Phase | Not Applicable |
| Drug / device / biological / vaccine name(s) | |
| Primary outcome measure | End systolic volume (ESV) in (ml) measured using a 2D echocardiogram at baseline and 6 months |
| Secondary outcome measures | 1. End diastolic volume (ESV) in (ml) measured using a 2D echocardiogram at baseline and 6 months 2. Ejection fraction (%) measured using a 2D echocardiogram at baseline and 6 months 3. Quality of life measured using a Minnesota Living with Heart Failure Questionnaire score at baseline and 6 months 4. Efficacy of device implant measured using clinical composite score at 6 months 5. Class of heart failure measured using NYHA class at baseline and 6 months |
| Overall study start date | 01/11/2018 |
| Completion date | 30/07/2022 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | Planned Sample Size: 218; UK Sample Size: 100 |
| Key inclusion criteria | 1. >= 18 years of age 2. Standard indication for CRT-P or CRT-D according to ESC/EHRA guidelines 3. Stable on optimal medical therapy for at least 3 months 4. Ischaemic aetiology 5. Patients with atrial fibrillation can be included |
| Key exclusion criteria | 1. Any contraindication to pacing/implantable cardioverter-defibrillator (ICD) implant 2. Requirement for endocardial pacing 3. Contraindication to magnetic resonance (MR) scanning 4. Claustrophobia 5. Significant renal impairment with estimated glomerular filtration rate (eGFR) < 30 ml/minute 6. Existing pacemaker or ICD system or extraction of a CRT system within the last 6 months 7. Be pregnant or plan to become pregnant over the next 7 months 8. Participation in other studies |
| Date of first enrolment | 05/07/2019 |
| Date of final enrolment | 05/07/2021 |
Locations
Countries of recruitment
- England
- United Kingdom
Study participating centres
Guy's Hospital
Great Maze Pond
London
SE1 9RT
United Kingdom
Whitechapel
London
E1 1BB
United Kingdom
Sponsor information
Hospital/treatment centre
c/o Jen Boston
R&D Department
16th Floor
Tower Wing
Great Maze Pond
London
SE1 9RT
England
United Kingdom
| Phone | +44 (0)2071889811 |
|---|---|
| R&D@gstt.nhs.uk | |
| Website | http://www.guysandstthomas.nhs.uk/Home.aspx |
University/education
c/o Reza Razavi
Division of Imaging Sciences and Biomedical Engineering
4th Floor Lambeth Wing
St Thomas' Hospital
London
SE1 7EH
England
United Kingdom
| Phone | +44 (0)2078483224 |
|---|---|
| reza.razavi@kcl.ac.uk |
Funders
Funder type
Industry
No information available
Results and Publications
| Intention to publish date | 30/07/2023 |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Data sharing statement to be made available at a later date |
| Publication and dissemination plan | 1. Additional documents unavailable but can be provided on request 2. Peer-reviewed scientific journals 3. Internal report 4. Conference presentation |
| IPD sharing plan | The data sharing plans for the current study are unknown and will be made available at a later date. |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| HRA research summary | 28/06/2023 | No | No |
Editorial Notes
24/06/2019: Trial's existence confirmed by the NIHR.
